Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA
genotypes in cytological cervical screening
- Authors:
- Jiaoying Cheng
- Meilu Bian
- Xiao Cong
- Aiping Sun
- Min Li
- Li Ma
- Ying Chen
- Jun Liu
View Affiliations
Affiliations: Department of Gynecology and Obstetrics, China-Japan Friendship Hospital, Beijing 100029, P.R. China
- Published online on: December 17, 2012 https://doi.org/10.3892/br.2012.49
-
Pages:
280-284
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
It has been confirmed that detection of high-risk human papillomavirus (HR HPV) DNA is useful in cervical cancer (CC) screening. Recently, a new real-time fluorescent polymerase chain reaction (PCR) assay was developed to detect HR HPV. This assay can synchronize nucleic acid amplification and testing using specific primers for 13 types of HR HPV genomes, combined with specific TaqMan fluorescent marker probe techniques through the fluorescence automatic PCR instrument. Furthermore, it uses TaqGold™ DNA polymerase, which minimizes the amount of non‑specific amplification and increases the sensitivity of the assay. The aim of this study was to evaluate the analytical and clinical performance of the real‑time fluorescent PCR assay in CC screening, compared to the Qiagen Hybrid Capture® II High‑Risk HPV DNA test® (HC II). In total, 1,252 cervical specimens were collected from women between 19 and 71 years of age. The specimens were examined with three different assays, real‑time fluorescent PCR assay and HC II for HR HPV detection combined with liquid‑based cytology. Women with cytological abnormalities or HR HPV‑positive results underwent colposcopy and cervical biopsy. This study demonstrated good overall agreement between HC II and real‑time fluorescent PCR assay (overall agreement, 92.25%; Cohen's κ=0.814). For the detection of high‑grade cervical intraepithelial neoplasias (CIN) and CC, the sensitivity of HC II and real‑time fluorescent PCR was 94.48 and 92.82%, respectively, and the negative predictive value was 98.85 and 98.54%, respectively. High HR HPV infection rate of the high‑grade CIN and CC group was detected (P<0.05). In conclusion, real-time fluorescent PCR assay provides similar results compared to the HC II test for HR HPV detection and could be used in CC screening in clinic.
View References
|
1
|
Munoz N, Bosch FX, de Sanjose S, Herrero
R, Castellsaque X, Shah KV, Snijders PJ and Meijer CJ;
International Agency for Research on Cancer Multicenter Cervical
Cancer Study Group: Epidemiologic classification of human
papilomavirus types associated with cervical cancer. N Engl J Med.
348:518–527. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ronco G, Biggeri A, Confortini M, et al:
Health technology assessment report: HPV DNA based primary
screening for cervical cancer precursors. Epidemiol Prev.
36:e1–e72. 2012.(In Italian).
|
|
3
|
Budenholzer B: ACP Journal Club. Adding
HPV testing to cytology screening reduced ≥grade 3 cervical
intraepithelial neoplasia at 5 years. Ann Intern Med. 157:JC2–JC7.
2012.PubMed/NCBI
|
|
4
|
Leinonen M, Nieminen P, Kotaniemi-Talonen
L, Malila N, Tarkkanen J, Laurila P and Anttila A: Age-specific
evaluation of primary human papillomavirus screening vs.
conventional cytology in a randomized setting. J Natl Cancer Inst.
101:1612–1623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davey DD and Zarbo RJ: Human
papillomarivus testing - are you ready for a new era in cervical
cancer screening? Arch Pathol Lab Med. 127:927–929. 2003.
|
|
6
|
Damasus-Awatai G and Freeman-Wang T: Human
papillomavirus and cervical screening. Curr Opin Obstet Gynecol.
15:473–477. 2003. View Article : Google Scholar
|
|
7
|
Petry KU, Menton S, Menton M, et al:
Inclusion of HPV testing in routine cervical cancer screening for
woman above 29 years in Germany: results for 8,466 patients. Br J
Cancer. 88:1570–1577. 2003.PubMed/NCBI
|
|
8
|
Wright TC Jr, Schiffman M, Solomon D, et
al: Interim guidance for the use of human papillomavirus DNA
testing as an adjunct to cervical cytology for screening. Obstet
Gynecol. 103:304–309. 2004. View Article : Google Scholar
|
|
9
|
Saslow D, Runowicz CD, Solomon D, et al:
American Cancer Society guideline for the early detection of
cervical neoplasia and cancer. CA Cancer J Clin. 52:342–362. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sherman ME, Lorincz AT, Scott DR, et al:
Baseline cytology, human papillomavirus testing, and risk for
cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst.
95:46–52. 2003.PubMed/NCBI
|
|
11
|
Sharma M, Bruni L, Diaz M, Castellsaqué X,
de Sanjosé SD, Bosch FX and Kim JJ: Using HPV prevalence to predict
cervical cancer incidence. Int J Cancer. Sep 11–2012.(Epub ahead of
print). View Article : Google Scholar
|
|
12
|
Castle PE, Schiffman M, Burk RD, et al:
Restricted cross-reactivity of hybrid capture 2 with nononcogenic
human papillomavirus types. Cancer Epidemiol Biomarkers Prev.
11:1394–1399. 2002.PubMed/NCBI
|
|
13
|
Poljak M, Marin IJ, Seme K and Vince A:
Hybrid Capture II HPV test detects at least 15 human papillomavirus
genotypes not included in its current high-risk probe cocktail. J
Clin Virol. 25:S89–S97. 2002. View Article : Google Scholar : PubMed/NCBI
|
